LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

LLY

1,003.74

-0.27%↓

JNJ

228.16

-0.98%↓

ABBV

210.05

-0.51%↓

UNH

392.67

-1.85%↓

AZN

181.16

-2.29%↓

Home・Elenco Azioni・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Aperta

SettoreSettore sanitario

21.8 -0.23

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

22.13

Metriche Chiave
By Trading Economics
Entrata	-29M -11M
Vendite	-24M 105M
EPS	-0.09
Margine di Profitto	-10.717
Dipendenti	354
EBITDA	-31M -8.5M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+59.66% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-281M 2.7B
Apertura precedente	22.03
Chiusura precedente	21.8

Notizie sul Sentiment di mercato

By Acuity

50%

171 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

12.42 / 14.93 Supporto e resistenza

Arcutis Biotherapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mag 2026, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mag 2026, 22:12 UTC

Utili

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mag 2026, 21:52 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs

15 mag 2026, 00:00 UTC

Utili

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mag 2026, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mag 2026, 23:56 UTC

Discorsi di Mercato

Gold Prices Rise on Strong Demand -- Market Talk

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mag 2026, 23:47 UTC

Utili

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mag 2026, 23:47 UTC

Utili

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mag 2026, 23:28 UTC

Discorsi di Mercato

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 mag 2026, 22:35 UTC

Discorsi di Mercato

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mag 2026, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mag 2026, 22:06 UTC

Discorsi di Mercato

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mag 2026, 22:04 UTC

Utili

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mag 2026, 22:00 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q EPS 18c >NU

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q Rev $4.97B >NU

Confronto tra pari

Modifica del prezzo

Arcutis Biotherapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

59.66% in crescita

Previsioni per 12 mesi

Media 34.63 USD 59.66%

Alto 36 USD

Basso 33 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Arcutis Biotherapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

12.42 / 14.93Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

171 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.